Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGX101 in Advanced Solid Tumors
NCT06440005Phase 1Recruiting
- Sponsor
- Angiex
- Start
- Jul 2024
- Primary completion
- Mar 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of AGX101 in solid tumor, breast cancer, prostate cancer (PCa) and 4 more (2 arms), sponsored by Angiex. Primary endpoints: Maximum Tolerated Dose at 21 days and Adverse Events up to 3 years. Started Jul 2024; status: recruiting.
02
Drugs
AGX101
03
Conditions
solid tumorbreast cancerprostate cancer (PCa)colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06440005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06440005.